-
مقتل الطفلة جوري الصوفي برصاصة داخل خيمة نزوح في مواصي خان يونس
-
Iraola says Isak 'feels the trust' after Liverpool scoring streak
-
بلدية الخليل: النزوح القسري تجاوز ثلاثة آلاف شخص مع استمرار الإخلاء والهدم
-
Tech firms gain on Anthropic IPO optimism; HSBC slumps in London
-
محمد الغول يدعو إلى وحدة فلسطينية لمواجهة مخاطر المرحلة
-
French media protest manhandling of journalists at far-right party rally
-
Sri Lanka end England hopes with crushing win over Pakistan
-
EU seeks deportation powers for beefed up border agency
-
ملاعب وأندية غزة تتحول إلى مراكز لإيواء العائلات النازحة
-
أميرات أوروبيات يخترن التدريب والخدمة في صفوف القوات المسلحة
-
Dangote, Nigeria's oil tycoon rewriting Africa's story
-
Two charged with UK security offences over airbase plot: police
-
Carrick to remain Man Utd boss for Chelsea clash: reports
-
الحزب الليبرالي يقبل فوز لولا ويتجه إلى مسار قانوني بشأن الحملة الانتخابية
-
Maresca defends Donnarumma, Guehi after Man City defeat
-
Greenhouse gas levels hit new record highs in 2025: UN
-
Nordic leaders call Putin as local truce begins in Ukraine
-
Rybakina looking to clinch year-end number one in Tokyo
-
Osaka unveils crane outfit in Tokyo before win over Paolini
-
Tech firms track Wall St rally on mixed day for stock markets
-
Ronaldo in line for Portugal return after fallout with coach
-
Kane says Ballon d'Or win 'feels like a dream' as tributes pour in
-
Norway media take legal action to block Meta from using content
-
HSBC profit jumps on higher rates, lower costs
-
Bayern praise 'humble' Kane after Ballon d'Or win
-
Rams rediscover offensive balance in 35-21 victory over Raiders
-
Colts retain Daniel Jones as starter despite continued offensive struggles
-
Mercedes-Benz cuts 2026 profit outlook on tough China market
-
Madushanka wrecks Pakistan as Sri Lanka press for final slot
-
Reparations calls follow Charles on tough Caribbean trip
-
Destructive Abhishek 113 leads India to series win over New Zealand
-
Jammu and Kashmir ministers resign before planned council expansion
-
Norway, Finland leaders hold 'frank and substantive' talk with Putin
-
Germany, EU, stable investment stops despite upheaval: Merz
-
Wall Street faces earnings and Fed tests after turbulent technology-led week
-
China brands drop Mbappe for 'offending national sentiments'
-
Ukraine, Russia say US-brokered truce holding in ravaged city
-
India orders evacuations as Cyclone Arnab looms
-
Police form SIT after vehicles in Rahul Gandhi convoy collide on expressway
-
Dutch broadcaster pulls out of Eurovision over Israel 'sensitivities'
-
Delhi grants minimum monthly pay and DA to about 4,000 MCD health workers
-
Critical coal inventories affect nearly half of India’s domestic power plants
-
Ather Energy shares climb 14% after quarterly profit and expansion plan
-
FCNR(B) deposit drive puts sharper margin pressure on private banks
-
Gold ETF flows turn negative after 13 weeks as bullion loses 4%
-
Noel Tata requests records of September 17 Tata Sons board meeting
-
Pakistan's last antique restorers give old treasures new life
-
Reparations calls to dog King Charles's tough Caribbean trip
-
India braces for Cyclone Arnab with evacuations
-
Global rates and foreign outflows remain key risks for Indian markets
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
A.AbuSaada--SF-PST